---
title: "Ultragenyx Pharmaceutical (RARE) news: lawsuit and settlement"
url: "https://aibio.space/companies/ultragenyx-pharmaceutical/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "RARE lawsuit and settlement news. Ultragenyx Pharmaceutical news for investors: Ultragenyx develops and sells treatments for rare genetic diseases…"
---

Desk view · Opinion · Updated Oct 22, 2026

## Ultragenyx trades pipeline risk for launch risk

Ultragenyx now has a commercial base, two new gene therapies and fresh voucher cash, but it has lost two phase 3 trials in nine months and has not yet shown launch revenue. The next year turns on launch numbers and the size of the cost cuts.

Read the full desk view

aibio.space Investor Rank · Opinion

**6** /10 Neutral view

Two gene therapy approvals and voucher cash support Ultragenyx, but two phase 3 failures in nine months, ongoing burn and a thin late-stage pipeline weigh on it.

- **Technology**: 2/2

- **Odds**: 1/2

- **Balance sheet**: 1/2

- **Risk**: 1/2

- **Momentum**: 1/2

Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank).

- **Technology**: **Commercial and proven.** Two AAV gene therapies are now FDA approved, and four products already bring in revenue.

- **Odds**: **Mixed record.** Two approvals landed, but two phase 3 trials failed in nine months. Rare disease programs reach approval 17.0% of the time from phase 1, per the BIO study.

- **Balance sheet**: **Helped by vouchers.** Cash was $436 million at June 30 with $413 million of voucher sales pending, against a $97 million quarterly operating burn.

- **Main risk**: **Launch execution.** Two high-priced gene therapies need payer and center uptake, and the late-stage pipeline is thin after Aspire.

- **Watch next**: **UX701 Wilson disease data in Q4 2026.** Also the Angelman program decision, expense cuts and voucher closings.

## Top news on Ultragenyx

1. 2026-10-19 Legal [Ultragenyx and Baylor settle Dojolvi patent litigation with Navinta, generic entry set for 2033](https://aibio.space/news/ultragenyx-baylor-settle-dojolvi-patent-litigation-navinta-generic/) The 8-K says the New Jersey case followed Navinta's generic application. Navinta gets a royalty-free license from January 1, 2033; suits against other filers continue.
2. 2026-10-14 Financings [Ultragenyx agrees to transfer two priority review vouchers for $413 million](https://aibio.space/news/ultragenyx-agrees-transfer-two-priority-review-vouchers-413-million/) The company will receive $210 million and $203 million in cash, subject to antitrust clearance. The NIH is owed 20% of the first sale.
3. 2026-06-23 Company Updates [Calidi Biotherapeutics appoints Corsee Sanders to board](https://aibio.space/news/calidi-biotherapeutics-appoints-corsee-sanders-board/) Dr. Corsee Sanders, a former Genentech/Roche and Celgene executive, joined the board as an independent director effective June 17, 2026.

## Dates

**Q4 2026**
Dose-finding data from the UX701 Cyprus2+ study in Wilson disease [Source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/0001193125-26-332802-index.htm)

**Second half 2026**
Decision on the apazunersen program and expense reductions; Aurora study enrollment expected to complete [Source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526380165/0001193125-26-380165-index.htm)

**Pending (no date given)**
Closing of the $210 million and $203 million priority review voucher sales, subject to Hart-Scott-Rodino clearance [Source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526421079/0001193125-26-421079-index.htm)

**First half 2027**
DTX301 phase 3 data on reduced treatment burden in OTC deficiency [Source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/0001193125-26-332802-index.htm)

## The money

Cash, cash equivalents and marketable securities of $436 million at June 30, 2026; net cash used in operations was $97 million in Q2. Two priority review voucher sales (gross $210 million and $203 million) are pending closing. The company targets profitability in 2027. [Source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/0001193125-26-332802-index.htm)

Total revenue of $214 million in Q2 2026 (Crysvita $156 million, Dojolvi $27 million, Evkeeza $21 million, Mepsevii $10 million). 2026 guidance: $730 million to $760 million, excluding new launches. [Source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/0001193125-26-332802-index.htm)

## Risks on the record

- Launch risk for two gene therapies priced at $3.95 million and $2.7 million; Genglycos carries accelerated approval with required post-marketing data on 50 patients and 20 controls. [Source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526357185/0001193125-26-357185-index.htm)
- Two consecutive phase 3 failures (setrusumab in December 2025, apazunersen in September 2026) while the company burns about $97 million of cash a quarter. [Source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526380165/0001193125-26-380165-index.htm)
- Dojolvi patent litigation with remaining generic filers is still pending; settled filers can enter from 2033. [Source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526424739/0001193125-26-424739-index.htm)

## Questions investors ask

### What is aibio.space's Investor Rank for Ultragenyx Pharmaceutical?

6 out of 10, our neutral view. Two gene therapy approvals and voucher cash support Ultragenyx, but two phase 3 failures in nine months, ongoing burn and a thin late-stage pipeline weigh on it. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank)

### Why did Ultragenyx stock fall in September 2026?

Its phase 3 Aspire trial of apazunersen in Angelman syndrome missed its primary and secondary endpoints on Sept. 2. Fierce Biotech reported shares fell 43% after hours. [Source](https://fiercebiotech.com/biotech/ultragenyx-fails-phase-3-angelman-test-plots-significant-expenses-reduction)

### What did the FDA approve for Ultragenyx in 2026?

Genglycos (DTX401) got accelerated approval on Aug. 19 for glycogen storage disease type Ia. Fayuvi (UX111) got standard full approval on Sept. 17 for Sanfilippo syndrome type A. [Source](https://www.sec.gov/Archives/edgar/data/1515673/000151567326000006/0001515673-26-000006-index.htm)

### How much cash does Ultragenyx have?

It reported $436 million in cash, equivalents and marketable securities at June 30, 2026. It has since agreed to transfer two priority review vouchers for $210 million and $203 million, pending closing. [Source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/0001193125-26-332802-index.htm)

### How much does Fayuvi cost?

Ultragenyx set a U.S. list price of $3.95 million per patient, according to Bioxconomy and Fierce Pharma. Genglycos is priced at $2.7 million. [Source](https://www.bioxconomy.com/modalities/fda-approves-gene-therapy-for-ultra-rare-childhood-metabolic-disease-will-cost-4m-per-patient)

### When will Ultragenyx be profitable?

The company has said it is on a path to profitability in 2027 and expects combined R&D and SG&A spending to fall by at least 15% that year compared with 2025. [Source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/0001193125-26-332802-index.htm)

### What is the latest Ultragenyx Pharmaceutical (RARE) stock news?

Our latest story on Ultragenyx Pharmaceutical, dated Oct 19, 2026: "Ultragenyx and Baylor settle Dojolvi patent litigation with Navinta, generic entry set for 2033". The 8-K says the New Jersey case followed Navinta's generic application. Navinta gets a royalty-free license from January 1, 2033; suits against other filers continue. [Source](https://aibio.space/news/ultragenyx-baylor-settle-dojolvi-patent-litigation-navinta-generic/)

### What is Ultragenyx Pharmaceutical's latest stock offering or financing news?

Our latest financing story, dated Oct 14, 2026: "Ultragenyx agrees to transfer two priority review vouchers for $413 million". The company will receive $210 million and $203 million in cash, subject to antitrust clearance. The NIH is owed 20% of the first sale. [Source](https://aibio.space/news/ultragenyx-agrees-transfer-two-priority-review-vouchers-413-million/)

### How much cash does Ultragenyx Pharmaceutical have?

From our story of Oct 14, 2026: The company will receive $210 million and $203 million in cash, subject to antitrust clearance. [Source](https://aibio.space/news/ultragenyx-agrees-transfer-two-priority-review-vouchers-413-million/)

### Is Ultragenyx Pharmaceutical facing a lawsuit?

Our latest legal story, dated Oct 19, 2026: "Ultragenyx and Baylor settle Dojolvi patent litigation with Navinta, generic entry set for 2033". The 8-K says the New Jersey case followed Navinta's generic application. Navinta gets a royalty-free license from January 1, 2033; suits against other filers continue. Claims in lawsuits are allegations until a court rules. [Source](https://aibio.space/news/ultragenyx-baylor-settle-dojolvi-patent-litigation-navinta-generic/)

### What is Ultragenyx Pharmaceutical's market cap?

We do not publish live share prices. In its annual report, Ultragenyx Pharmaceutical Inc. put the market value of shares held by non-affiliates (public float) at $3.40 billion as of Jun 30, 2025. Source

### Is Ultragenyx Pharmaceutical a smaller reporting company?

SEC records list Ultragenyx Pharmaceutical Inc.'s filer category as: Large accelerated filer. Source

### Where is Ultragenyx Pharmaceutical headquartered?

SEC records list its business address as 60 LEVERONI COURT, NOVATO, CA, 94949. Source

### When does Ultragenyx Pharmaceutical's fiscal year end?

Ultragenyx Pharmaceutical Inc.'s fiscal year ends on December 31, per SEC records. Source

### What did Ultragenyx Pharmaceutical last file with the SEC?

Its most recent filing in our record is an 8-K filed 2026-10-19. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526424739/rare-20261019.htm)

## Legal and investor matters

Checked against Ultragenyx Pharmaceutical filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026.

1. 2026-10-19 Litigation Ultragenyx settles Dojolvi patent suit with Navinta, generic license from 2033 Ultragenyx said in an 8-K that on October 19, 2026 it and Baylor Research Institute settled with Navinta LLC the patent litigation over Dojolvi in the U.S. District Court for the District of New Jersey. Ultragenyx will grant Navinta a non-exclusive, royalty-free license to market a generic version beginning January 1, 2033, extended to July 1, 2033 if pediatric exclusivity is granted. Similar suits against other filers remain pending. The settlement goes to the FTC and DOJ. U.S. District Court for the District of New Jersey · Status: settled [Ultragenyx 8-K filed 2026-10-19](https://www.sec.gov/Archives/edgar/data/1515673/000119312526424739/rare-20261019.htm)
2. 2026-10-08 Financing Ultragenyx agrees to sell two priority review vouchers for $210 million and $203 million Ultragenyx disclosed in two 8-Ks that it agreed to sell two Rare Pediatric Disease Priority Review Vouchers for cash. On October 6, 2026 it agreed to sell the voucher awarded August 19, 2026 for Genglycos for $210 million. On October 8, 2026 it agreed to sell the voucher awarded September 17, 2026 for Fayuvi for $203 million. Each sale is subject to closing conditions, and 20% of the first sale goes to the NIH. [Ultragenyx 8-K filed 2026-10-14](https://www.sec.gov/Archives/edgar/data/1515673/000119312526421079/rare-20261008.htm)
3. 2026-05-06 Derivative suit Stockholder derivative complaint filed against Ultragenyx directors over UX143 trials Ultragenyx reported in its 10-Q filed May 6, 2026 that in March 2026 a putative stockholder derivative complaint was filed in the U.S. District Court for the Northern District of California. It names board members, the CEO and the Chief Medical Officer as defendants and the company as nominal defendant. The complaint alleges breaches of fiduciary duty, violations of Section 14(a) and gross mismanagement tied to the UX143 Orbit and Cosmic trials, and seeks unspecified damages. U.S. District Court for the Northern District of California · Status: pending [Ultragenyx 10-Q filed 2026-05-06](https://www.sec.gov/Archives/edgar/data/1515673/000119312526206960/rare-20260331.htm)
4. 2026-02-18 Class action Putative securities class action filed against Ultragenyx, CEO and CMO over UX143 trials Ultragenyx's 10-K filed February 18, 2026 reports that in February 2026 Steven Bailey filed a putative class action on behalf of certain stockholders against the company, its CEO and its Chief Medical Officer in the Northern District of California. The complaint asserts claims under Sections 10(b) and 20(a) of the Exchange Act, alleging false and misleading statements about the design and prospects of the UX143 Orbit and Cosmic trials. It seeks unspecified damages. U.S. District Court for the Northern District of California · Status: pending [Ultragenyx 10-K filed 2026-02-18](https://www.sec.gov/Archives/edgar/data/1515673/000119312526057329/rare-20251231.htm)
5. 2026-02-12 Other Ultragenyx begins restructuring with 10% workforce reduction Ultragenyx said in an 8-K that on February 12, 2026 it began a strategic restructuring plan to reduce expenses, including a 10% workforce reduction of approximately 130 employees. The company estimated total restructuring and related charges of about $50 million, with about $10 million for severance and employee costs and about $40 million for terminating UX143 manufacturing agreements and related activities, mostly in the first half of 2026. [Ultragenyx 8-K filed 2026-02-12](https://www.sec.gov/Archives/edgar/data/1515673/000119312526048738/rare-20260212.htm)
6. 2025-12-29 Other Ultragenyx reports Phase 3 setrusumab Orbit and Cosmic studies missed primary endpoints Ultragenyx said in an 8-K that on December 29, 2025 it announced results from the Phase 3 Orbit and Cosmic studies of setrusumab (UX143) in osteogenesis imperfecta. Neither study achieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate. Both studies achieved the secondary endpoints of improvements in bone mineral density. The securities class action and derivative complaint filed in 2026 relate to these trials. [Ultragenyx 8-K filed 2025-12-29](https://www.sec.gov/Archives/edgar/data/1515673/000119312525332422/rare-20251229.htm)
7. 2025-11-03 Financing Ultragenyx sells additional Crysvita royalty interest to OMERS vehicle for $400 million Ultragenyx disclosed in an 8-K that on November 3, 2025 it and its subsidiary Rare Delaware Inc. entered into a royalty purchase agreement with OCM LS23 Holdings LP, an investment vehicle of OMERS. OMERS paid $400 million in cash for the right to an additional 25% of future Crysvita royalty payments due from Kyowa Kirin in the United States and Canada from January 1, 2028, and a further 30% from a later date. [Ultragenyx 8-K filed 2025-11-04](https://www.sec.gov/Archives/edgar/data/1515673/000119312525264707/rare-20251103.htm)
8. 2024-11-06 Litigation Ultragenyx sues Catalent in Delaware over manufacturing agreement Ultragenyx reported in its 10-Q filed November 6, 2024 that on October 9, 2024 it filed suit against Catalent Maryland, Inc. and Catalent Pharma Solutions in Delaware Superior Court, alleging fraudulent misrepresentation of manufacturing capabilities and breaches of a manufacturing agreement. The later 10-Q filed August 5, 2026 says Catalent counterclaimed in January 2026 for about $8 million over disputed invoices, and that discovery is ongoing. Superior Court of the State of Delaware · Status: pending [Ultragenyx 10-Q filed 2024-11-06](https://www.sec.gov/Archives/edgar/data/1515673/000095017024121679/rare-20240930.htm)

## Pipeline

| Program | Indication | Stage |
|---|---|---|
| Fayuvi (UX111, AAV9 gene therapy) | Sanfilippo syndrome type A (MPS IIIA) | FDA approved Sept. 17, 2026 (standard full approval) [Source](https://www.sec.gov/Archives/edgar/data/1515673/000151567326000006/0001515673-26-000006-index.htm) |
| Genglycos (DTX401, AAV8 gene therapy) | Glycogen storage disease type Ia | FDA accelerated approval Aug. 19, 2026 [Source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526357185/0001193125-26-357185-index.htm) |
| UX701 (AAV9 gene therapy) | Wilson disease | Pivotal Cyprus2+ study, dose-finding stage [Source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/0001193125-26-332802-index.htm) |
| DTX301 (AAV8 gene therapy) | OTC deficiency | Phase 3 Enh3ance, second endpoint data expected 1H 2027 [Source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/0001193125-26-332802-index.htm) |
| Apazunersen (GTX-102, antisense) | Angelman syndrome | Phase 3 Aspire failed Sept. 2, 2026; Aurora phase 2/3 enrolling; program under review [Source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526380165/0001193125-26-380165-index.htm) |

Opinion · Devil's advocate

## Fact-check-o-meter

Some gaps

Ultragenyx reports setbacks plainly, but its August framing now sits beside a cost-cutting plan

Ultragenyx's filings describe the Angelman failure and the earlier setrusumab misses without spin, and its liquidity language is conventional (no going concern warning). The gaps are about timing and emphasis: the August release reaffirmed a 2027 profitability path about four weeks before a failed phase 3 and a plan for significant expense cuts, and the 10-Q keeps a positive reading of setrusumab after two missed primary endpoints. A securities class action over the setrusumab trials is pending.

1. Press release vs filing · weight medium 2027 profitability path reaffirmed, then expense cuts flagged four weeks later **The company said:** "Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R&D and SG&A expenses to be flat to slightly down versus 2025; remain on path to profitability in 2027" [source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/rare-ex99_1.htm) **The record says:** The Sept. 2 8-K says: "The Company will also assess its planned operations to define and implement significant expense reductions, while supporting its growing commercial business." The 10-Q says cash, cash equivalents and marketable securities were $436 million at June 30, 2026 and that capital resources "will be sufficient to fund our projected operating requirements for at least the next 12 months". [source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526380165/rare-20260902.htm) **Our view:** Nothing here contradicts the filings, and no going concern doubt is raised. But the August guidance was set before Aspire read out, and the documents reviewed do not say whether the 2027 profitability target still stands.
2. Science · weight high Angelman phase 3 was randomized and sham controlled, and showed no efficacy signal **The company said:** "we are ready to launch two gene therapy products and are preparing for a pivotal Phase 3 GTX-102 data readout in Angelman syndrome" [source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/rare-ex99_1.htm) **The record says:** The Sept. 2 8-K says the study "did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index" and "There were no differences between the treated and control groups that could support efficacy". ClinicalTrials.gov lists 129 participants, quadruple masking and the same Bayley-4 primary endpoint at Day 338. [source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526380165/rare-20260902.htm) **Our view:** The company reported the result in neutral terms, which is fair. A sham-controlled phase 3 found no efficacy signal, and the remaining Aurora study is described in the release as open-label, so it cannot supply a randomized comparison.
3. Science · weight medium Genglycos approval rests on a randomized phase 3 with 44 evaluable patients; the confirmatory controls are external **The record says:** The Aug. 19 8-K says approval is based on the "48-week randomized, double-blind, placebo-controlled Phase 3 GlucoGene study" that "treated 46 participants" with 44 in the mITT population (DTX401 n=20, placebo n=24), "showing a reduction in the cornstarch requirements in the treated group (p<0.001)". As a condition of accelerated approval, the company will follow "50 patients and 20 control patients", where the controls are patients "who sought commercial treatment but cannot be treated with GENGLYCOS due to the presence of anti-AAV8 antibodies". ClinicalTrials.gov lists the primary endpoint as percent change in daily cornstarch intake at Week 48. [source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526357185/rare-20260819.htm) **Our view:** The approval study was randomized and placebo controlled. Cornstarch intake is a burden measure rather than a hard clinical outcome, and the post-marketing controls are not randomized. Antibody-positive patients may differ from treated ones, so the confirmatory data will be harder to interpret than a randomized study.
4. Science · weight medium 10-Q keeps a positive reading of setrusumab after two missed primary endpoints **The record says:** The 10-Q says the phase 3 Orbit and Cosmic studies "did not achieve their primary endpoint of reduction in annualized clinical fracture rate", then adds: "We believe the data across two global Phase 3 studies suggest that setrusumab has a meaningful effect on bone disease in OI." It adds that the company will "continue to engage regulatory agencies to determine the necessary data to support a regulatory filing and if there is a potential path forward for UX143." [source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526333233/rare-20260630.htm) **Our view:** The miss is stated first and clearly. The 10-Q says the January data included bone mineral density, vertebral fractures and patient reported outcomes but does not say which measures support the belief, so readers should treat it as management's view and not a regulatory position.
5. Legal and disclosure record · weight medium Securities class action and derivative suit over the setrusumab trials **The record says:** The 10-Q's Legal Proceedings lists Steven Bailey v. Ultragenyx Pharmaceutical Inc., Emil D. Kakkis, and Eric Crombez, M.D., a putative class action filed in February 2026 in the U.S. District Court for the Northern District of California under Sections 10(b) and 20(a) of the Exchange Act. The complaint is described as "alleging that the Company made false and misleading statements about the design and prospects of the UX143 Orbit and Cosmic clinical trials." A putative derivative complaint was filed in the same court in March 2026. The 10-Q also lists Hatch-Waxman patent suits over Dojolvi; on Oct. 19 the company settled with Navinta (generic entry from Jan. 1, 2033), and similar suits against other filers remain pending. [source](https://www.sec.gov/Archives/edgar/data/1515673/000119312526333233/rare-20260630.htm) **Our view:** These are allegations in complaints, not findings. The 10-Q says the complaints seek unspecified damages and gives no loss estimate.

Documents we compared

- [Press release: second quarter 2026 results (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/rare-ex99_1.htm) 2026-08-04
- [Form 10-Q for quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/1515673/000119312526333233/rare-20260630.htm) 2026-08-05
- [Form 8-K: Genglycos accelerated approval](https://www.sec.gov/Archives/edgar/data/1515673/000119312526357185/rare-20260819.htm) 2026-08-19
- [Form 8-K: Aspire phase 3 results for apazunersen](https://www.sec.gov/Archives/edgar/data/1515673/000119312526380165/rare-20260902.htm) 2026-09-02
- [Form 8-K: Fayuvi approval](https://www.sec.gov/Archives/edgar/data/1515673/000151567326000006/rare-20260917.htm) 2026-09-17
- [Form 8-K: priority review voucher sale](https://www.sec.gov/Archives/edgar/data/1515673/000119312526421079/rare-20261008.htm) 2026-10-14
- [Form 8-K: Dojolvi patent settlement with Navinta](https://www.sec.gov/Archives/edgar/data/1515673/000119312526424739/rare-20261019.htm) 2026-10-19
- [ClinicalTrials.gov NCT06617429 (Aspire)](https://clinicaltrials.gov/study/NCT06617429) 2026-08-06
- [ClinicalTrials.gov NCT05139316 (GlucoGene)](https://clinicaltrials.gov/study/NCT05139316) 2026-10-14

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply).

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:RARE on TradingView](https://www.tradingview.com/symbols/NASDAQ-RARE/).

## SEC filings and registration

- **SEC name**: Ultragenyx Pharmaceutical Inc.

- **CIK**: 1515673

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: RARE (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Large accelerated filer

- **Business address**: 60 LEVERONI COURT, NOVATO, CA, 94949

- **Phone**: 415-483-8800

- **Shares outstanding**: 98,588,873 as of 2026-07-31 (10-Q filed 2026-08-05)

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1515673/000119312526424739/rare-20261019.htm) filed 2026-10-19
- [8-K](https://www.sec.gov/Archives/edgar/data/1515673/000119312526421079/rare-20261008.htm) filed 2026-10-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1515673/000119312526416251/rare-20261006.htm) filed 2026-10-07
- [8-K](https://www.sec.gov/Archives/edgar/data/1515673/000151567326000006/rare-20260917.htm) filed 2026-09-17
- [8-K](https://www.sec.gov/Archives/edgar/data/1515673/000119312526380165/rare-20260902.htm) filed 2026-09-02
- [8-K](https://www.sec.gov/Archives/edgar/data/1515673/000119312526357185/rare-20260819.htm) filed 2026-08-19
- [8-K](https://www.sec.gov/Archives/edgar/data/1515673/000119312526343525/rare-20260807.htm) filed 2026-08-11
- [10-Q](https://www.sec.gov/Archives/edgar/data/1515673/000119312526333233/rare-20260630.htm) filed 2026-08-05

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001515673), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/ultragenyx-pharmaceutical/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Ultragenyx Pharmaceutical (RARE) news: lawsuit and settlement", 2026-10-31, https://aibio.space/companies/ultragenyx-pharmaceutical/